Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
1 mg
5 mg
10 mg
1 mM
2.3172 mL
11.5861 mL
23.1723 mL
5 mM
0.4634 mL
2.3172 mL
4.6345 mL
10 mM
0.2317 mL
1.1586 mL
2.3172 mL
50 mM
0.0463 mL
0.2317 mL
0.4634 mL
Description
NVP 231 is a novel inhibitor that inhibits the catalytic activity of recombinant CerK in vitro with an IC50 of 12 nM. NVP 231 induces cell apoptosis by increasing DNA fragmentation and .
NVP-231 reduces cell viability and DNA synthesis by triggering cell death of cancer cells. NVP-231-treated cells committed M phase arrest rather than arrest at the G2/M boundary. In MCF-7 and NCI-H358 cells, NVP-231 treatment causes a concentration-dependent up-regulation of cyclin B1 phosphorylation at Ser133 and a reduction of CDK1 phosphorylation at Tyr15. Wee1 is down-regulated by NVP-231 in both NCI-H358 and MCF-7 cells. Upon NVP-231 treatment of cancer cells, CDK4 protein is concentration- and time-dependently down-regulated. This effect is even more pronounced in synchronized cells.
